1. P536: VALUE OF MEASURABLE RESIDUAL DISEASE BY MULTIPARAMETRIC FLOW CYTOMETRY IN NON-PROMYELOCYTIC ACUTE MYELOID LEUKEMIA. REAL WORLD EVIDENCE. (23rd June 2022) Authors: Gimenez Conca, A. D.; Gonzalez, J.; Rivas, M. M.; Navickas, A.; Fernandez, I.; Rey, I.; Dick, H.; Cranco, S.; Moirano, M.; Ferrari, L.; Clavijo, M.; Suero, A.; Ramirez, R.; Basquiera, A. L.; Carnelutto, N.; Rapan, M. L.; Jorge Alberto, A.; Belli, C. Journal: HemaSphere Issue: Volume 6(2022)Supplement 3 Page Start: 435 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. PB1829: ARGENTINEAN REAL WORLD EXPERIENCE ON MIDOSTAURIN PLUS INTENSIVE CHEMOTHERAPY VS INTENSIVE CHEMOTHERAPY TO TREAT FLT3 POSITIVE ACUTE MYELOID LEUKEMIA PATIENTS. (23rd June 2022) Authors: Navickas, A.; González, J.; Rivas, M. M.; Clavijo, M.; Carnelutto, N.; Funes, M. E.; Mela Osorio, M. J.; Mariano, R.; Rapan, M. L.; Moirano, M.; Rey, I.; Cranco, S.; Giunta, J. E.; Ramirez, R.; Castro, M. B.; Enrico, A.; Gimenez Conca, A.; Belli, C. Journal: HemaSphere Issue: Volume 6(2022)Supplement 3 Page Start: 1709 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗